After taking a long look at the inquiry into Circle Medical’s billing practices by the U.S. Attorney’s Office, Raymond James ...

As reported by the Globe and Mail, McReynolds April 9 maintained his “Sector Perform” rating on BCE while cutting his price target on the stock from $39.00 to $37.00. The analyst says visibility has ...

Following a key product update, Raymond James analyst Michael W. Freeman remains bullish on Medexus Pharmaceuticals ...

New year, new CEO. Can Lip-Bu Tan make a difference for Intel ( Intel Stock Quote, Chart, News, Analysts, Financials ...

The new go-private price for Converge Technology Solutions is $6.00 and Ventum Capital Markets analyst Rob Goff thinks that ...

He’s has a “Buy” rating on the stock, but TD Cowen analyst Vince Valentini thinks 2025 could be a rocky road for Rogers ...

The biggest Liberation Day winner”. That’s where Citi analyst James Hardiman thinks BRP stands in the North American travel ...

What’s the latest on Donald Trump’s tariffs? You might want to check your watch, not your calendar say economists at RBC.

Delayed financials from WELL Health mean an opportunity for investors, says Ventum Capital Markets analyst Rob Goff.

Following the company’s most recent acquisition, Haywood analyst Neal Gilmer has maintained his “Buy” rating on Organigram.

Following the company’s fourth quarter results, RBC analyst Paul Treiber has cut his price target on BlackBerry ...

Its fourth quarter results are in the books and Haywood analyst Neal Gilmer has maintained his “Buy” rating on Rubicon ...